Werkgroep Cardiologische centra Nederland

AUGUSTUS (Completed)

An open-label, 2 x 2 factorial, randomized controlled, clinical trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspririn vs. aspririn placebo in patients with atrial fibrillation and ACS or PCI
Medicine
apixaban
Population
ASCVD
Phase
IV
Starting year
2015
More information
ClinicalTrials.gov

Director of Study

dr. M.E.W. Hemels (Cardioloog)
Arnhem, Rijnstate Ziekenhuis